Takeda revealed on Wednesday that it is thinking to obtain Shire, which led to rise in its share by 25 percent. It also revealed that there has been no approach made to Shire’s board and the proposal is at a “preparatory and exploratory” stage. No information about the investment was revealed by the Japanese drug makers. Takeda after acquiring Shire will flourish in the market of therapeutic areas of oncology, gastrointestinal disorders and neuroscience. The acquisition of Shire’s rare-disease franchise will give an upper hand to Takeda and will pace up its path to become the pioneer in specialised medicine. This will be also profitable to the Shire as this would increase Shire market opportunities in the US. According to the UK acquisition regulations Takeda should give the final decision about its Shire acquisition by April 25. The other pharma companies such as AbbVie, Novartis, Pfizer will still be the part of the bidding process which might lead to higher pricing in the bidding race.